==========
Sequence Listing could not be accepted.
If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).
Reviewer: Anne Corrigan
Timestamp: [year=2010; month=7; day=20; hr=9; min=9; sec=38; ms=742;]
==========

****
Reviewer Comments:
<210> 42
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = Asn or Gln, Xaa at position 3 = any amino acid residue

<400> 42

Gln Xaa Xaa Xaa Gln
1   5

The above <223> response contains an error: "Xaa at position 3" is shown twice; the third "Xaa" is at positioin 4.

Minor errors below:

<210> 10
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = an y amino acid residue, Xaa at position 4 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa at position 6 = any amino acid resdue

<400> 10

Pro Xaa Xaa Xaa Thr Xaa
1   5

The above <223> response explaining Xaa contains a misspelling: please replace "resdue" with "residue".

<210> 40
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position = Thr or Ser

<400> 40

Pro Xaa Asn Xaa Thr
1   5

In the last <223> response (explaining the "Xaa" at location 4: please correct it to read "Xaa at position 4 = Thr or Ser"
****

Validated By CRFValidator v 1.0.3

Application No: 10559758 Version No: 3.0

Input Set:

Output Set:

Started: 2010-07-19 17:39:10.333
Finished: 2010-07-19 17:39:13.068
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 735 ms
Total Warnings: 62
Total Errors: 0
No. of SeqIDs Defined: 62
Actual SeqID Count: 62

Error code		Error Description
W	213	Artificial or Unknown found in <213> in SEQ ID (1)
W	213	Artificial or Unknown found in <213> in SEQ ID (2)
W	213	Artificial or Unknown found in <213> in SEQ ID (3)
W	213	Artificial or Unknown found in <213> in SEQ ID (4)
W	213	Artificial or Unknown found in <213> in SEQ ID (5)
W	213	Artificial or Unknown found in <213> in SEQ ID (6)
W	213	Artificial or Unknown found in <213> in SEQ ID (7)
W	213	Artificial or Unknown found in <213> in SEQ ID (8)
W	213	Artificial or Unknown found in <213> in SEQ ID (9)
W	213	Artificial or Unknown found in <213> in SEQ ID (10)
W	213	Artificial or Unknown found in <213> in SEQ ID (11)
W	213	Artificial or Unknown found in <213> in SEQ ID (12)
W	213	Artificial or Unknown found in <213> in SEQ ID (13)
W	213	Artificial or Unknown found in <213> in SEQ ID (14)
W	213	Artificial or Unknown found in <213> in SEQ ID (15)
W	213	Artificial or Unknown found in <213> in SEQ ID (16)
W	213	Artificial or Unknown found in <213> in SEQ ID (17)
W	213	Artificial or Unknown found in <213> in SEQ ID (18)
W	213	Artificial or Unknown found in <213> in SEQ ID (19)
W	213	Artificial or Unknown found in <213> in SEQ ID (20)

Input Set:

Output Set:

Started: 2010-07-19 17:39:10.333
Finished: 2010-07-19 17:39:13.068
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 735 ms
Total Warnings: 62
Total Errors: 0
No. of SeqIDs Defined: 62
Actual SeqID Count: 62

Error code	Error Description

This error has occured more than 20 times, will not be displayed

SEQUENCE LISTING

<110> Hart, Stephen Lewis
Writer, Michele

<120> PEPTIDE LIGANDS

<130> ABL-012.1P US

<140> 10559758
<141> 2010-07-19

<150> GB 03 13132.3
<151> 2003-06-06

<150> PCT/GB2004/002421
<151> 2004-06-07

<160> 62

<170> PatentIn version 3.5

<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = a
ny amino acid residue, Xaa at position 4 = any amino acid residue

<400> 1

Pro Xaa Xaa Xaa Thr
1 5

<210> 2
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa at position 3 = any amino acid residue

<400> 2

Pro Ser Xaa Ser
1

<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid, Xaa at position 3 = any amino acid having an amide side chain, Xaa at position 4 = any amino acid

<400> 3

Gln Xaa Xaa Xaa Gln
1 5

<210> 4
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue having an aliphatic side chain

<400> 4

Ser Xaa Ser
1

<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<400> 5

Pro Xaa Leu Xaa Thr
1 5

<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 6

Pro Ala Leu Lys Thr
1 5

<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<400> 7

Pro Xaa Asn Xaa Thr
1 5

<210> 8
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 8

Pro Ser Asn Ser Thr
1 5

<210> 9
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 9

Pro Pro Asn Thr Thr
1 5

<210> 10
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = an y amino acid residue, Xaa at position 4 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa at position 6 = any amino acid resdue

<400> 10

Pro Xaa Xaa Xaa Thr Xaa
1 5

<210> 11
<211> 6

<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa at position 6 = any amino acid residue

<400> 11

Pro Xaa Leu Xaa Thr Xaa
1 5

<210> 12
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa at position 6 = any amino acid residue

<400> 12

Pro Xaa Asn Xaa Thr Xaa
1 5

<210> 13
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (3)..(5)
<223> Xaa at position 3 = any amino acid residue, Xaa at position 4 = a
ny amino acid residue, Xaa at position 5 = any amino acid residue

<400> 13

Xaa Pro Xaa Xaa Xaa Thr
1 5

<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (3)..(5)
<223> Xaa at position 3 = any amino acid residue, Xaa at position 4 = a
ny amino acid residue, Xaa at position 5 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa at position 7 = any amino acid residue

<400> 14

Xaa Pro Xaa Xaa Xaa Thr Xaa
1 5

<210> 15
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 15

Ala Pro Ser Asn Ser Thr Ala
1 5

<210> 16
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 16

Ser Pro Ala Leu Lys Thr Val
1 5

<210> 17
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 17

Ser Thr Pro Pro Asn Thr Thr
1 5

<210> 18
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 18

Pro Ser Asn Ser
1

<210> 19
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 19

Pro Ser Leu Ser
1

<210> 20
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 = Ala or Lys

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<400> 20

Xaa Pro Ser Xaa Ser
1 5

<210> 21
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 21

Ala Pro Ser Asn Ser
1 5

<210> 22
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 22

Leu Pro Ser Leu Ser
1   5

<210> 23
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 23

Met Leu Pro Ser Leu Ser
1   5

<210> 24
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 24

Pro Met Leu Pro Ser Leu Ser
1   5

<210> 25
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 25

Ser Gln Lys Asn Pro Gln Met
1   5

<210> 26
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 26

Phe Gln Ser Gln Tyr Gln Lys
1   5

<210> 27
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 27

Met Ala Ser Ile Ser Met Lys
1   5

<210> 28
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 28

Asp Trp Trp His Thr Ser Ala
1   5

<210> 29
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 29

Ser His Val Lys Leu Asn Ser
1   5

<210> 30
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 30

Gln Leu Leu Thr Gly Ala Ser
1 5

<210> 31
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 31

Thr Ala Arg Asp Tyr Arg Leu
1 5

<210> 32
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 32

Phe Pro Arg Ala Pro His His
1 5

<210> 33
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 33

Ser Glu Trp Leu Ser Ala Leu
1 5

<210> 34
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 34

Ile Gly Gly Ile Arg Arg His
1 5

<210> 35
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 35

Tyr Thr Met Glu Phe Asn Arg
1 5

<210> 36
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<400> 36

Pro Ala Ala Tyr Lys Ala His
1 5

<210> 37
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = a
ny amino acid residue, Xaa at position 4 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa at position 6 = Ala or Val

<400> 37

Pro Xaa Xaa Xaa Thr Xaa
1 5

<210> 38
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue,

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue,

<400> 38

Pro Xaa Asn Xaa Thr
1 5

<210> 39
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A
sn or Leu, Xaa at position 4 = any amino acid residue

<400> 39

Pro Xaa Xaa Xaa Thr
1 5

<210> 40
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position = Thr or Ser

<400> 40

Pro Xaa Asn Xaa Thr
1   5

<210> 41
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 = Ala or Leu

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<400> 41

Xaa Pro Ser Xaa Ser
1   5

<210> 42
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A
       sn or Gln, Xaa at position 3 = any amino acid residue

<400> 42

Gln Xaa Xaa Xaa Gln
1 5

<210> 43
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide binding to dendritic cells

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = Leu or Ile

<400> 43

Ser Xaa Ser
1

<210> 44
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 44

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Ser His Val Lys Leu Asn Ser Cys Gly
20 25

<210> 45
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 45

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Ala Pro Ser Asn Ser Thr Ala Cys Gly
            20   25

<210> 46
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 46

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gly
            20   25

<210> 47
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 47

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Phe Pro Arg Ala Pro His His Cys Gly
            20   25

<210> 48
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 48

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Asp Trp Trp His Thr Ser Ala Cys Gly

20 25

<210> 49
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 49

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly
20 25

<210> 50
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 50

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Ala Thr Arg Trp Ala Arg Glu Cys Gly
20 25

<210> 51
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 51

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Arg Arg Glu Glu Trp Ala Cys Gly
20 25

<210> 52
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 52

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gln
20 25

<210> 53
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> integrin-binding peptide

<400> 53

Arg Arg Glu Thr Glu Trp Ala
1 5

<210> 54
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic nucleic acid binding domain

<400> 54

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

<210> 55
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> hydrophobic spacer sequence

<220>
<221> MISC_FEATURE

<222> (1)..(1)
<223> x = epsilon-amino hexanoic acid residue

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> x = epsilon-amino hexanoic acid residue

<400> 55

Xaa Ser Xaa Gly Ala
1 5

<210> 56
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 56
ccctcattag cgtaacg 17

<210> 57
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> control peptide

<400> 57

Ala Thr Arg Trp Ala Arg Glu
1 5

<210> 58
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide encoding peptide ligand

<400> 58
ccggaagcca cgtcaagctg aacg 24

<210> 59
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary oligonucleotide encoding SEQ ID NO:29

<400> 59
ccggcgctgt tcagcttcac gtggctt 27

<210> 60
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide ligand

<400> 60

Ala Pro Thr